RHYTHM PHARMACEUTICALS INC

For the period ended Dec 31, 2023. Filed Feb 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 29, 2024

RYTM$113.95+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)


· · Year Ended · · Year Ended · · Year Ended
· · December 31, · · December 31, · · December 31,
	2023		2022		2021
Revenues:
Product revenue, net		$77,428		$16,884		$3,154
License revenue		—		6,754		—
Total revenues		77,428		23,638		3,154
Costs and expenses:
Cost of sales		9,302		2,133		599
Research and development		134,951		108,630		104,128
Selling, general, and administrative		117,532		92,032		68,486
Total costs and expenses		261,785		202,795		173,213
Loss from operations		(184,357)		(179,157)		(170,059)
Other income (expense):
Other income (expense), net		190		(790)		100,000
Interest expense		(13,892)		(5,201)		—
Interest income		13,945		4,029		447
Total other income (expense), net		243		(1,962)		100,447
Loss before income taxes		(184,114)		(181,119)		(69,612)
Provision for income taxes		564		—		—
Net loss		$(184,678)		$(181,119)		$(69,612)
Net loss per share, basic and diluted		$(3.20)		$(3.47)		$(1.40)
Weighted-average common shares outstanding, basic and diluted		57,673,128		52,120,701		49,600,294

Other comprehensive loss:
Net loss		$(184,678)		$(181,119)		$(69,612)
Foreign currency translation adjustment		(140)		—		—
Unrealized gain (loss), net on marketable securities		366		(91)		(1)
Comprehensive loss		$(184,452)		$(181,210)		$(69,613)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.